Microneedle Biosensor Enables Real-Time Drug Clearance Monitoring and Early Detection of Kidney and Liver Dysfunction
Key Insights
A new microneedle biosensor demonstrated the ability to monitor drug clearance in real time while detecting early kidney and liver dysfunction (search) in preclinical rat models.
The device showed superior durability and sensitivity compared to existing biosensors, maintaining stable performance for up to 6 days in freely moving animals.
The biosensor detected renal impairment earlier than conventional biomarker thresholds and accurately tracked recovery during therapeutic intervention.
A novel microneedle biosensor has demonstrated the ability to monitor drug clearance in real time while detecting early kidney and liver dysfunction (search) in preclinical models, offering a minimally invasive approach for precision medicine monitoring. The device represents a significant advancement in wearable biosensor technology, addressing key limitations of existing monitoring systems.
Addressing Current Biosensor Limitations
Wearable biosensors hold promise for transforming therapeutic drug monitoring, but many current devices struggle with low sensitivity and damage during tissue insertion. The research team developed a resilient nanostructured bioelectrode (RNB) microneedle sensor designed to improve signal quality and durability while continuously sampling interstitial fluid. The platform aims to support drug dosing decisions and enable earlier recognition of organ dysfunction through real-time measurements.
Advanced Microneedle Design and Performance
The study evaluated a microneedle sensor fabricated using a bilayer process with a micrometer-thick gold adhesion layer and controlled dealloying to reduce stress. Compared with a nanodendrite bioelectrode, the device maintained better sensor response after tissue insertion. The microneedle sensor remained corrosion resistant, stable over a wide potential window, and abrasion immune in megapascal-stiff tissues.
"We paired our nanocavity-textured microneedle electrode with a bioanalytical framework that translates interstitial fluid measurements into blood-equivalent pharmacokinetic parameters," explains Sam Emaminejad, one of the study's researchers.
Preclinical Validation in Drug Monitoring
In freely moving rat models, the sensor extended in vivo biosensor lifetime for pharmacokinetics monitoring to 6 days. Using a blood interstitial fluid equilibrium framework, investigators accurately derived blood-equivalent pharmacokinetic parameters. The potential of this RNB for therapeutic drug monitoring in vivo was confirmed by the concordance between the RNB data and blood levels of the liver-metabolized chemotherapy drug irinotecan in healthy rats.
Liver Function Assessment
In hepatic experiments, the device identified delayed clearance of irinotecan in liver-damaged models. The biosensor data showed prolonged drug half-life in rats with liver damage, demonstrating its capability to detect hepatic dysfunction through altered drug metabolism patterns.
Kidney Function Monitoring
For renal assessment, recordings correlated with blood antibiotic pharmacokinetics across chronic kidney disease (search) severities. The RNB data from vancomycin-treated healthy rats correlated strongly with the dose-dependent changes in drug levels measured in blood. In rats with adenine-induced kidney injury, the biosensor data not only showed lower drug clearance concordant with a reduction in glomerular filtration rate but also reflected improvements in kidney function when animals were allowed to recover for 2 weeks from the high-adenine diet.
Notably, the platform detected renal impairment earlier than conventional biomarker thresholds through drug clearance quantification. Early in the disease induction phase, RNB-detectable decreases in drug clearance preceded the increase in blood creatinine levels, suggesting superior sensitivity for early dysfunction detection.
Clinical Translation Potential
These findings suggest that the microneedle sensor could enable longitudinal monitoring of low-concentration analytes without repeated blood sampling. Clinically, this technology may help optimize dosing for narrow therapeutic index medicines and provide earlier warning of declining renal or hepatic function.
The device's ability to capture recovery during therapeutic intervention also positions it as a valuable tool for monitoring treatment response and adjusting therapeutic strategies in real time. Further studies in humans are needed to confirm safety, calibration stability, long-term wearability, and performance across diverse patient groups and medication classes.